← feed

Is NCT03385525 results overdue?

Yes — results are overdue. Primary completion was 2017-10-13; the FDAAA-801 reporting deadline (2018-10-13) passed 2808 days ago and no results are posted on ClinicalTrials.gov.

Study to Evaluate the Effect of UGT Inhibition by Valproic Acid on the Pharmacokinetics of BIIB074

NCT IDNCT03385525 ↗
SponsorBiogen (INDUSTRY)
Public issuerBIOGEN INC. — BIIB (CIK 0000875045) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2017-10-13 (ACTUAL)
Reporting deadline2018-10-13 (completion + 365d)
Days overdue2808
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 d44a5d0e7e2a1166… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03385525. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →